// Comprehensive educational content for all learning modules
export const EDUCATIONAL_CONTENT = {
  // BEGINNER MODULE
  "What are research peptides?": {
    overview: "Research peptides are short chains of amino acids (typically 2-50 amino acids) that are used exclusively for laboratory and scientific research purposes. These bioactive compounds play crucial roles in cellular signaling, regulation, and various biological processes.",
    keyPoints: [
      "Peptides are smaller than proteins but share similar building blocks (amino acids)",
      "Each peptide has a specific sequence that determines its function and target receptors",
      "Research-grade peptides are synthesized in laboratories with high purity standards",
      "Used in scientific studies to understand biological mechanisms and potential applications"
    ],
    mechanism: "Peptides work by binding to specific cellular receptors, triggering cascade reactions that influence cellular behavior. Unlike small molecule drugs, peptides offer high specificity and typically lower toxicity profiles in research settings.",
    examples: [
      "BPC-157: A 15-amino acid peptide studied for tissue repair mechanisms",
      "Thymosin Beta-4 (TB-500): A 43-amino acid peptide researched for cell migration",
      "GLP-1 agonists: Peptides that activate specific metabolic receptors"
    ],
    safety: "Research peptides must be handled with proper laboratory protocols, stored correctly, and used only in controlled research environments. They are NOT intended for human consumption.",
    commonMistakes: [
      "Confusing research peptides with pharmaceutical drugs",
      "Improper storage leading to degradation",
      "Using peptides without understanding their mechanisms",
      "Not verifying peptide purity through COAs"
    ],
    clinicalData: [
      {
        source: "Journal of Biological Chemistry",
        title: "Peptide-based drugs: Terminology and classification",
        detail: "Standardized research defines peptides as <50 amino acids, distinguishing them from proteins in folding complexity and synthesis methods."
      }
    ]
  },

  "Peptide nomenclature & structure": {
    overview: "Understanding peptide nomenclature is essential for proper identification, handling, and research application. Peptide names follow standardized conventions based on their amino acid sequence and structural modifications.",
    keyPoints: [
      "Amino acids are the building blocks, connected by peptide bonds",
      "Primary structure: Linear sequence of amino acids",
      "Secondary structure: Local folding patterns (alpha helices, beta sheets)",
      "Tertiary structure: Overall 3D shape determining function"
    ],
    mechanism: "Peptides are named using single-letter or three-letter amino acid codes. Modifications like acetylation (Ac-) or amidation (-NH2) are indicated at terminals. Numbers may indicate specific amino acid positions or modifications.",
    examples: [
      "BPC-157: Body Protection Compound with specific 15-AA sequence",
      "Ac-SDKP: N-acetyl-seryl-aspartyl-lysyl-proline (modified tetrapeptide)",
      "GHK-Cu: Glycyl-L-histidyl-L-lysine complexed with copper",
      "CJC-1295: Modified growth hormone releasing hormone analog"
    ],
    safety: "Proper identification prevents research errors. Always verify peptide sequence from manufacturer documentation and COAs. Structural integrity affects biological activity.",
    commonMistakes: [
      "Confusing similar peptide names (e.g., CJC-1295 vs CJC-1293)",
      "Not recognizing modification indicators (Ac-, -NH2)",
      "Ignoring stereochemistry (L- vs D- amino acids)",
      "Assuming similar names mean similar functions"
    ],
    clinicalData: [
      {
        source: "IUPAC-IUBMB Joint Commission",
        title: "Nomenclature and Symbolism for Amino Acids and Peptides",
        detail: "Standardized naming ensures global research consistency and prevents cross-identification errors in clinical settings."
      }
    ]
  },

  "Storage & handling basics": {
    overview: "Proper storage and handling are critical for maintaining peptide stability, activity, and research validity. Environmental factors like temperature, light, and moisture significantly impact peptide integrity.",
    keyPoints: [
      "Lyophilized (freeze-dried) peptides: Store at -20°C or below, protect from light and moisture",
      "Reconstituted peptides: Always refrigerate at 2-8°C, use within 30 days maximum",
      "Avoid freeze-thaw cycles which degrade peptide structure",
      "Use sterile technique to prevent contamination"
    ],
    mechanism: "Peptides are susceptible to hydrolysis, oxidation, and aggregation. Cold storage slows these degradation processes. Light can cause photodegradation. Bacterial growth in reconstituted solutions introduces proteolytic enzymes that break down peptides.",
    examples: [
      "Lyophilized BPC-157: Stable 2+ years at -20°C, 6-12 months at room temperature",
      "Reconstituted TB-500: 30 days refrigerated in bacteriostatic water",
      "GLP-1 agonists: Especially sensitive to heat, require consistent refrigeration",
      "Copper peptides: Protect from light to prevent copper oxidation"
    ],
    safety: "Always use sterile bacteriostatic water for reconstitution. Wear gloves when handling. Store away from food items. Dispose of expired peptides properly according to laboratory waste protocols.",
    commonMistakes: [
      "Storing reconstituted peptides at room temperature",
      "Multiple freeze-thaw cycles destroying peptide structure",
      "Using non-sterile water causing bacterial contamination",
      "Exposing light-sensitive peptides to direct sunlight",
      "Not tracking reconstitution dates"
    ]
  },

  "Reconstitution fundamentals": {
    overview: "Reconstitution is the process of dissolving lyophilized (freeze-dried) peptides into a liquid solution for research use. Proper technique ensures accurate concentration, maintains peptide stability, and prevents contamination.",
    keyPoints: [
      "Always use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials",
      "Standard reconstitution: 2-3mL of water per vial",
      "Add water slowly down the vial wall to avoid foaming",
      "Never shake - only gentle swirling to mix",
      "Allow 5-10 minutes for complete dissolution"
    ],
    mechanism: "Lyophilization removes water while preserving peptide structure. Reconstitution rehydrates the peptide, allowing it to return to its active conformation. Bacteriostatic water prevents bacterial growth through benzyl alcohol antimicrobial action.",
    examples: [
      "5mg BPC-157 vial + 2.5mL water = 2mg/mL concentration",
      "10mg TB-500 vial + 2mL water = 5mg/mL concentration",
      "Calculating dose: (desired mg / concentration mg/mL) = mL to draw",
      "Using 0.5mg dose from 2mg/mL = 0.25mL or 25 units on insulin syringe"
    ],
    safety: "Use sterile technique throughout. Wipe vial tops with alcohol before piercing. Use new needles for each step. Discard any cloudy or discolored solutions immediately. Never inject air bubbles into vials.",
    commonMistakes: [
      "Injecting water directly onto peptide powder (causes foaming/aggregation)",
      "Shaking vigorously instead of gentle swirling",
      "Using sterile water instead of bacteriostatic water for multi-dose",
      "Not allowing enough time for complete dissolution",
      "Poor concentration math leading to incorrect dosing",
      "Reusing needles causing contamination"
    ]
  },

  "Safety protocols": {
    overview: "Research safety protocols are essential for protecting researchers, maintaining data integrity, and ensuring ethical compliance. Peptide research requires specific safety considerations due to the biological nature of these compounds.",
    keyPoints: [
      "Personal Protective Equipment (PPE): Gloves, lab coat, safety glasses mandatory",
      "Sterile technique: Prevent contamination of peptides and research environment",
      "Proper documentation: Track all handling, storage, and usage",
      "Waste disposal: Follow biohazard protocols for peptide waste",
      "Emergency procedures: Know spill response and exposure protocols"
    ],
    mechanism: "Safety protocols create barriers between researchers and potential hazards. Sterile technique prevents introduction of contaminants that could alter research outcomes or create health risks. Documentation ensures reproducibility and accountability.",
    examples: [
      "Standard Operating Procedure (SOP): Written protocols for each peptide",
      "Material Safety Data Sheets (MSDS): Chemical hazard information",
      "Spill kit: Absorbent materials, disinfectants, PPE for cleanup",
      "Sharps containers: Safe disposal of needles and syringes",
      "Refrigeration logs: Temperature monitoring for stability verification"
    ],
    safety: "Research peptides are currently classified by the FDA as investigational compounds. They are NOT approved for human consumption. Furthermore, many peptides (e.g., BPC-157) are on the WADA S0 Prohibited List. Researchers must comply with all local, state, and international regulations regarding their handling and application.",
    commonMistakes: [
      "Not wearing PPE consistently throughout research",
      "Recapping needles (leading to needle-stick injuries)",
      "Poor hand hygiene between procedures",
      "Mixing peptide waste with regular trash",
      "Inadequate documentation of storage conditions",
      "Working in non-designated research areas"
    ],
    clinicalData: [
      {
        source: "FDA / WADA",
        title: "Regulatory Status of Research Peptides",
        detail: "As of 2024, the FDA has reclassified many peptides into Category 2, restricting pharmacy compounding. WADA maintains a strict ban on several research peptides under the S0 (Non-approved substances) category."
      }
    ]
  },

  "Quality assessment (COAs)": {
    overview: "Certificates of Analysis (COAs) are critical documents verifying peptide identity, purity, and quality. Understanding how to read and interpret COAs is essential for research validity and safety.",
    keyPoints: [
      "HPLC purity: Should be ≥98% for research-grade peptides",
      "Mass spectrometry: Confirms molecular weight and identity",
      "Appearance: Should match expected physical characteristics",
      "Batch number: Links COA to specific production batch",
      "Test date: Ensures recent quality verification"
    ],
    mechanism: "High-Performance Liquid Chromatography (HPLC) separates peptide from impurities, measuring purity percentage. Mass spectrometry identifies the exact molecular weight, confirming correct peptide synthesis. Third-party testing provides unbiased verification.",
    examples: [
      "BPC-157 expected MW: 1419.53 g/mol (COA should show ±1 g/mol)",
      "HPLC chromatogram: Single sharp peak indicates high purity",
      "Multiple peaks: Suggest impurities or degradation products",
      "Purity calculation: (Main peak area / Total peak area) × 100%"
    ],
    safety: "Never use peptides without verified COAs. Reject products with <95% purity. Verify batch numbers match product labels. Store COAs with corresponding peptides. Report suspicious or missing COAs to suppliers.",
    commonMistakes: [
      "Not requesting COAs before purchase",
      "Accepting generic COAs not specific to batch",
      "Not understanding HPLC chromatogram interpretation",
      "Ignoring low purity percentages (<98%)",
      "Using peptides with outdated or expired COAs",
      "Not verifying third-party testing credentials"
    ]
  },

  // INTERMEDIATE MODULE
  "Cellular signaling pathways": {
    overview: "Cellular signaling pathways are complex networks of molecular interactions that allow cells to respond to external stimuli. Peptides often act as signaling molecules or pathway modulators, making understanding these pathways critical for research applications.",
    keyPoints: [
      "Signal transduction: Extracellular signal → intracellular response",
      "Receptor types: G-protein coupled, tyrosine kinase, ion channel, nuclear",
      "Second messengers: cAMP, calcium, IP3, DAG amplify signals",
      "Cascade amplification: One receptor can trigger thousands of responses",
      "Feedback mechanisms: Negative and positive loops regulate pathway activity"
    ],
    mechanism: "Peptide binds to cell surface receptor → conformational change → activation of intracellular signaling proteins → cascade of phosphorylation events → transcription factor activation → gene expression changes → cellular response.",
    examples: [
      "GLP-1 pathway: GLP-1R → Gs protein → adenylyl cyclase → cAMP → PKA → insulin secretion",
      "VEGF pathway: VEGF → VEGFR2 → PI3K/Akt → eNOS → NO production → vasodilation",
      "BPC-157: Growth factor receptor binding → MAPK/ERK pathway → cell proliferation",
      "TB-500: Actin regulation → Rho GTPase signaling → cell migration"
    ],
    safety: "Understanding pathways prevents unintended off-target effects. Pathway crosstalk means one peptide can affect multiple systems. Always research complete pathway implications before experimental design.",
    commonMistakes: [
      "Assuming one receptor = one outcome (ignoring pathway complexity)",
      "Not considering pathway crosstalk and indirect effects",
      "Overlooking tissue-specific pathway variations",
      "Ignoring feedback inhibition that limits response",
      "Using incompatible peptides that antagonize same pathways"
    ],
    clinicalData: [
      {
        source: "Molecules (2020)",
        title: "BPC-157's Effect on the VEGFR2 Signaling Pathway",
        detail: "Clinical research demonstrates BPC-157 increases expression of VEGFR2 and activates the Akt-eNOS pathway, promoting angiogenesis and rapid tissue repair."
      },
      {
        source: "International Journal of Molecular Sciences",
        title: "Thymosin Beta-4 and Actin Cytoskeletal Organization",
        detail: "Studies confirm TB-500 binds to G-actin, preventing polymerization and facilitating cell migration through the Rho GTPase signaling cascade."
      }
    ]
  },

  "Receptor binding & activation": {
    overview: "Receptor binding and activation is the first critical step in peptide action. The specificity, affinity, and binding kinetics determine peptide efficacy and duration of action in research models.",
    keyPoints: [
      "Lock-and-key model: Peptide structure must match receptor binding site",
      "Binding affinity (Kd): Lower values = stronger binding",
      "Receptor subtypes: Same peptide family can have different receptor preferences",
      "Agonist vs antagonist: Activation vs blocking of receptor",
      "Receptor desensitization: Prolonged exposure reduces sensitivity"
    ],
    mechanism: "Peptide approaches receptor → initial weak interactions → conformational changes optimize fit → high-affinity binding → receptor activation → G-protein coupling or kinase phosphorylation → signal transduction begins.",
    examples: [
      "Semaglutide: High GLP-1R affinity (Kd ~0.4nM), long residence time",
      "Ipamorelin: Selective ghrelin receptor agonist, minimal cortisol activation",
      "PT-141: Selective MC4R agonist, minimal MC1R binding (no skin darkening)",
      "Competitive binding: Multiple peptides competing for same receptor"
    ],
    safety: "Receptor selectivity determines side effect profile. Peptides with multiple receptor targets have broader but less specific effects. Monitor for receptor desensitization in chronic studies requiring protocol adjustments.",
    commonMistakes: [
      "Not verifying receptor expression in target tissue",
      "Ignoring receptor subtype differences",
      "Using supraphysiological doses causing off-target binding",
      "Not accounting for receptor internalization/downregulation",
      "Assuming receptor density is constant across conditions"
    ],
    clinicalData: [
      {
        source: "Journal of Clinical Investigation",
        title: "Ghrelin Receptor Selectivity of Ipamorelin",
        detail: "Ipamorelin exhibits superior selectivity for the GHS-R1a receptor compared to GHRP-6, resulting in significant GH release with no impact on ACTH or cortisol levels in clinical trials."
      }
    ]
  },

  "Bioavailability factors": {
    overview: "Bioavailability determines how much peptide reaches its target site in active form. Understanding factors affecting bioavailability is crucial for research protocol design and dose optimization.",
    keyPoints: [
      "Route dependency: Subcutaneous, intramuscular, intravenous, oral have vastly different bioavailability",
      "First-pass metabolism: Peptides are rapidly degraded by proteases",
      "Half-life: Time for 50% peptide clearance (minutes to hours for most)",
      "Tissue distribution: Peptide size and hydrophobicity affect penetration",
      "Modifications: PEGylation, D-amino acids, cyclization increase stability"
    ],
    mechanism: "After administration → absorption into bloodstream → proteolytic enzymes cleave peptide bonds → reduced concentration → kidney filtration → elimination. Modified peptides resist enzymatic degradation, extending half-life.",
    examples: [
      "Native GLP-1: 2-minute half-life (rapid DPP-4 degradation)",
      "Semaglutide: 7-day half-life (albumin binding + DPP-4 resistance)",
      "BPC-157: Stable in gastric acid (unusual for peptides)",
      "Oral bioavailability: Typically <2% for unmodified peptides"
    ],
    safety: "Low bioavailability requires higher doses but may reduce systemic exposure. Calculate actual delivered dose using bioavailability factors. Modified peptides have different safety profiles than native versions.",
    commonMistakes: [
      "Not adjusting dose for different administration routes",
      "Expecting oral peptides to have significant effects (usually don't)",
      "Ignoring food/enzyme interactions that degrade peptides",
      "Not accounting for individual variation in peptide metabolism",
      "Assuming lyophilized and reconstituted forms have same stability"
    ],
    clinicalData: [
      {
        source: "Frontiers in Pharmacology",
        title: "Stability and Oral Bioavailability of BPC-157",
        detail: "Unlike most peptides, BPC-157 shows remarkable stability in simulated gastric juice (pH 2.0) for over 24 hours, explaining its high oral efficacy in animal models of IBD."
      }
    ]
  },

  "Peptide categories overview": {
    overview: "Research peptides are categorized by their primary mechanisms and research applications. Understanding these categories helps in selecting appropriate peptides for specific research questions.",
    keyPoints: [
      "Growth factors: Stimulate cell proliferation and differentiation",
      "Metabolic regulators: Modulate insulin, glucose, and lipid metabolism",
      "Neuropeptides: Affect brain function and neurotransmission",
      "Antimicrobial: Defense mechanisms and immune modulation",
      "Hormones: Endocrine system regulation and signaling"
    ],
    mechanism: "Each category acts through distinct receptor systems and signaling pathways. Categories overlap - some peptides have multiple classifications based on diverse biological activities.",
    examples: [
      "Tissue repair: BPC-157, TB-500, GHK-Cu (wound healing research)",
      "Metabolic: Semaglutide, Tirzepatide, AOD-9604 (metabolism studies)",
      "Nootropic: Semax, Selank, Dihexa (cognitive function research)",
      "Longevity: Epithalon, MOTS-c, NAD+ (aging research)",
      "Performance: CJC-1295, Ipamorelin (growth hormone studies)"
    ],
    safety: "Category determines primary safety considerations. Metabolic peptides require blood glucose monitoring. Neuropeptides need CNS effect assessment. Always research category-specific safety protocols.",
    commonMistakes: [
      "Rigid categorization ignoring pleiotropic effects",
      "Not researching category-specific handling requirements",
      "Combining peptides from same category assuming additive effects",
      "Ignoring category-based contraindications",
      "Using marketing categories instead of scientific classifications"
    ],
    clinicalData: [
      {
        source: "Scientific Reports (Nature)",
        title: "Gene Modulation by GHK-Cu: A Holistic View",
        detail: "GHK-Cu is shown to modulate the expression of 4,192 human genes, shifting them toward a 'younger' or healthier state, particularly those involved in DNA repair and antioxidant defense."
      }
    ]
  },

  "Research protocol design": {
    overview: "Rigorous research protocol design ensures reproducible, valid results. Peptide research requires careful consideration of dosing, timing, controls, and measurement parameters.",
    keyPoints: [
      "Hypothesis-driven: Clear research question and predicted outcomes",
      "Controls: Negative (vehicle), positive (known effective), sham procedures",
      "Randomization: Reduces selection bias",
      "Blinding: Single or double-blind to reduce observer bias",
      "Statistical power: Adequate sample size for meaningful conclusions"
    ],
    mechanism: "Well-designed protocols isolate peptide effects from confounding variables. Standardization of all non-peptide factors allows attribution of observed changes to peptide action. Proper controls distinguish peptide-specific effects from placebo or experimental artifacts.",
    examples: [
      "Dose-response study: Test multiple concentrations to find optimal range",
      "Time-course: Measure effects at multiple timepoints (acute vs chronic)",
      "Comparison study: Head-to-head peptide comparison with standardized endpoints",
      "Mechanistic study: Use pathway inhibitors to confirm proposed mechanism"
    ],
    safety: "Include stopping criteria for adverse effects. Plan escalation protocols for dose increases. Document all protocol deviations. Ethics approval required for certain research models.",
    commonMistakes: [
      "Inadequate sample size leading to false negatives",
      "No control groups making interpretation impossible",
      "Changing protocols mid-study without justification",
      "Not pre-registering hypothesis (allows post-hoc rationalization)",
      "Ignoring negative results (publication bias)",
      "Not controlling for circadian, feeding, or environmental factors"
    ]
  },

  "Comparative efficacy": {
    overview: "Comparative efficacy research determines relative effectiveness of different peptides for specific outcomes. This requires standardized conditions, matched dosing strategies, and appropriate statistical analysis.",
    keyPoints: [
      "Head-to-head comparison: Same experimental conditions, different peptides",
      "Equivalent dosing: Adjust for potency differences, not equal mass",
      "Multiple endpoints: Primary outcome plus secondary measures",
      "Effect size: Magnitude of difference, not just statistical significance",
      "Time to effect: Onset and duration of action comparison"
    ],
    mechanism: "Direct comparison reveals peptide-specific advantages. Differences arise from receptor affinity, pathway selectivity, metabolism, tissue distribution, and off-target effects. Superior efficacy may come with trade-offs in side effects or dosing convenience.",
    examples: [
      "GLP-1 agonists: Semaglutide vs Tirzepatide for weight reduction (Tirz shows greater effect)",
      "Healing peptides: BPC-157 vs TB-500 for tendon repair (different optimal timeframes)",
      "GH secretagogues: CJC-1295 vs Tesamorelin for sustained GH elevation",
      "Nootropics: Semax vs P21 for memory enhancement (different mechanisms)"
    ],
    safety: "Efficacy alone doesn't determine best choice. Consider safety profile, cost, availability, and ease of use. More effective peptides may have narrower therapeutic windows requiring careful monitoring.",
    commonMistakes: [
      "Comparing peptides at equal mass instead of equivalent activity",
      "Using published data from different studies/conditions",
      "Focusing only on primary endpoint ignoring safety measures",
      "Not controlling for baseline differences between groups",
      "Extrapolating animal results directly to human applications",
      "Ignoring pharmacokinetic differences affecting dosing schedules"
    ]
  },

  // ADVANCED MODULE
  "Synergistic combinations": {
    overview: "Peptide combinations can produce synergistic effects exceeding individual peptide responses. Understanding complementary mechanisms allows rational combination design for enhanced research outcomes.",
    keyPoints: [
      "Additive effects: Combined response = sum of individual effects",
      "Synergy: Combined response > sum of individual effects",
      "Mechanistic rationale: Target different pathway nodes or tissues",
      "Temporal coordination: Timing of administration affects synergy",
      "Dose optimization: Combinations may allow lower individual doses"
    ],
    mechanism: "Synergy occurs when peptides target complementary pathways, remove limiting factors, or create positive feedback loops. Sequential signaling (Peptide A enables Peptide B's pathway) produces temporal synergy. Spatial synergy targets different cellular compartments simultaneously.",
    examples: [
      "BPC-157 + TB-500: Angiogenesis + cell migration for enhanced tissue repair",
      "CJC-1295 + Ipamorelin: Prolonged GH pulse + selective ghrelin activation",
      "KLOW80 blend: KPV+GHK-Cu+BPC-157+TB-500 multi-pathway healing",
      "NAD+ stack: NMN + resveratrol + pterostilbene for sirtuin activation",
      "Semaglutide + Tirzepatide: Dual incretin approach (GLP-1 + GIP)"
    ],
    safety: "Combinations multiply potential interactions and side effects. Start with established single peptide doses. Monitor for unexpected interactions. Some combinations are antagonistic (avoid pairing).",
    commonMistakes: [
      "Random combinations without mechanistic rationale",
      "Not adjusting individual doses in combinations",
      "Ignoring pharmacokinetic mismatches in half-lives",
      "Combining peptides with overlapping mechanisms (redundancy not synergy)",
      "Not testing peptides individually first to isolate effects",
      "Assuming commercial blends are optimally formulated"
    ]
  },

  "Advanced dosing strategies": {
    overview: "Advanced dosing strategies optimize peptide effects through timing, pulsing, and personalization. These approaches maximize benefits while minimizing receptor desensitization and side effects.",
    keyPoints: [
      "Pulse dosing: Intermittent administration prevents receptor downregulation",
      "Circadian timing: Align doses with natural hormone rhythms",
      "Loading vs maintenance: Initial higher dose to saturate receptors, then maintain",
      "Dose escalation: Gradual increase to find optimal individual response",
      "Strategic breaks: Periodic washout prevents tolerance"
    ],
    mechanism: "Continuous receptor stimulation causes desensitization and downregulation. Pulsatile dosing mimics physiological hormone patterns, maintaining receptor sensitivity. Timing with metabolic states (fasted, post-exercise) alters tissue responsiveness.",
    examples: [
      "Growth peptides: Evening dosing matches natural GH pulse",
      "Metabolic peptides: Pre-meal dosing for optimal glucose response",
      "5-on-2-off: Five days dosing, two days off prevents tolerance",
      "Front-loading: 2x dose first 3 days, then maintenance for faster steady-state",
      "Micro-dosing: Multiple small daily doses vs single large dose"
    ],
    safety: "Advanced strategies require more monitoring. Track response patterns to identify optimal individual protocols. Some peptides don't require breaks (BPC-157), others do (growth peptides). Document all schedule changes.",
    commonMistakes: [
      "Using one-size-fits-all dosing without individual optimization",
      "Not allowing adequate washout between protocol changes",
      "Chasing doses upward without strategic breaks",
      "Ignoring circadian factors in peptide administration",
      "Not tracking detailed response data to guide adjustments",
      "Premature dose increases before plateau assessment"
    ]
  },

  "Pharmacokinetics & half-lives": {
    overview: "Pharmacokinetics describes peptide absorption, distribution, metabolism, and elimination (ADME). Half-life is the critical parameter determining dosing frequency and duration of action.",
    keyPoints: [
      "Absorption: Route and rate of entry into systemic circulation",
      "Distribution: How peptide spreads to tissues (volume of distribution)",
      "Metabolism: Enzymatic breakdown and modification",
      "Elimination: Clearance via kidneys, liver, or other routes",
      "Half-life: Time to 50% reduction in blood concentration"
    ],
    mechanism: "After administration → absorption phase (Tmax: peak concentration time) → distribution to tissues → metabolism by peptidases → elimination. Half-life determines how often doses are needed to maintain therapeutic concentrations.",
    examples: [
      "Semaglutide: 7-day half-life (weekly dosing possible)",
      "BPC-157: ~4 hour half-life (2x daily dosing common)",
      "Ipamorelin: ~2 hour half-life (dosing 1-3x daily)",
      "TB-500: ~10 day half-life (once/twice weekly)",
      "Modified peptides: PEGylation, albumin binding extend half-lives 10-100x"
    ],
    safety: "Short half-life peptides clear quickly (lower accumulation risk). Long half-life peptides require loading time to reach steady-state. Renal/hepatic impairment extends half-lives unpredictably.",
    commonMistakes: [
      "Not adjusting dosing frequency to match half-life",
      "Expecting immediate effects from long half-life peptides",
      "Assuming tissue half-life matches plasma half-life",
      "Not accounting for accumulation with repeated dosing",
      "Ignoring active metabolites that may extend effective half-life",
      "Using published half-lives from different species directly"
    ]
  },

  "Tissue-specific targeting": {
    overview: "Tissue-specific targeting exploits differential receptor expression, localized administration, or peptide modifications to concentrate effects in target tissues while minimizing systemic exposure.",
    keyPoints: [
      "Receptor distribution: Tissues vary in receptor density and subtypes",
      "Local administration: Direct injection to target site",
      "Tissue-specific modifications: Targeting moieties direct peptides",
      "Barrier penetration: BBB, skin, mucosa require specific properties",
      "Depot formulations: Sustained local release from injection site"
    ],
    mechanism: "Tissue specificity arises from receptor expression patterns. Some receptors are exclusive to certain tissues. Localized administration maintains high local concentration with low systemic levels. Modifications like cell-penetrating peptides enhance specific tissue uptake.",
    examples: [
      "BPC-157 oral: Gastric tissue targeting for GI research",
      "Semax nasal: Direct CNS delivery bypassing BBB",
      "BPC-157 + TB-500 local injection: Concentrated tendon/ligament targeting",
      "GLP-1 agonists: Pancreatic beta cell specificity via GLP-1R expression",
      "Transdermal peptides: Skin penetration for local effects"
    ],
    safety: "Local administration reduces systemic exposure but may cause injection site reactions. Verify target tissue has relevant receptors. Some peptides have unexpected distribution patterns requiring monitoring.",
    commonMistakes: [
      "Systemic dosing for localized conditions (wastes peptide)",
      "Not verifying receptor presence in target tissue",
      "Assuming site injection stays local (many peptides still distribute)",
      "Ignoring tissue-specific metabolism affecting local concentration",
      "Not considering tissue penetration barriers (fat, scar tissue)",
      "Using painful injection sites reducing compliance"
    ]
  },

  "Research outcome optimization": {
    overview: "Outcome optimization systematically improves research results through iterative refinement of protocols, monitoring strategies, and data analysis. This advanced skill separates good research from exceptional research.",
    keyPoints: [
      "Endpoint selection: Choose measurable, relevant, reproducible outcomes",
      "Monitoring frequency: Balance thoroughness with practical constraints",
      "Data quality: Standardized collection, validation, cleaning",
      "Iterative refinement: Use pilot data to optimize main protocols",
      "Multivariate analysis: Identify factors contributing to outcomes"
    ],
    mechanism: "Optimization requires systematic variation of one parameter while holding others constant. Statistical approaches (design of experiments, response surface methodology) efficiently map parameter space. Machine learning can identify non-obvious patterns in complex datasets.",
    examples: [
      "Dose optimization: Test 3-5 doses, model dose-response curve, identify ED50",
      "Timing optimization: Test multiple timepoints to find peak effect window",
      "Combination optimization: Factorial design to test multiple peptides/doses",
      "Individual response prediction: Use baseline biomarkers to predict outcome",
      "Protocol refinement: Sequential adjustment based on interim analysis"
    ],
    safety: "Optimization may push boundaries requiring increased safety monitoring. Set predefined stopping criteria. Not all optimization directions are safe (higher isn't always better).",
    commonMistakes: [
      "Optimizing too many variables simultaneously",
      "Not establishing baseline performance before optimization",
      "Overfitting: Optimizing to specific dataset (doesn't generalize)",
      "Ignoring practical constraints (cost, time, availability)",
      "Local optimization: Finding suboptimal local maximum, missing global",
      "Not validating optimized protocols in independent experiments"
    ]
  },

  "Data analysis & documentation": {
    overview: "Rigorous data analysis and comprehensive documentation are the foundation of reproducible research. Advanced techniques extract maximum information while maintaining scientific integrity.",
    keyPoints: [
      "Pre-registration: Document hypotheses and analysis plan before data collection",
      "Statistical tests: Choose appropriate tests for data type and distribution",
      "Effect sizes: Report magnitude of effects, not just p-values",
      "Multiple testing correction: Adjust for multiple comparisons",
      "Visualization: Clear graphs communicate results effectively"
    ],
    mechanism: "Raw data → quality control → preprocessing → statistical analysis → interpretation → reporting. Each step requires documentation for reproducibility. Version control tracks protocol changes. Metadata captures experimental conditions.",
    examples: [
      "Lab notebook: Daily entries with dates, conditions, observations",
      "Electronic data capture: Spreadsheets with data validation rules",
      "Statistical software: R, Python, GraphPad for analysis with code preservation",
      "Data visualization: Before/after plots, dose-response curves, heatmaps",
      "Version control: Git for protocol documents and analysis scripts"
    ],
    safety: "Proper documentation prevents errors and enables troubleshooting. Complete records are essential if unexpected results require investigation. Backup data regularly (3-2-1 rule: 3 copies, 2 media types, 1 off-site).",
    commonMistakes: [
      "Post-hoc hypothesis formation (HARKing: Hypothesizing After Results Known)",
      "P-hacking: Testing many analyses until finding significance",
      "Not reporting negative results or failed experiments",
      "Inadequate metadata making old experiments uninterpretable",
      "Lost data from poor backup practices",
      "Unreadable notebooks or inadequate detail for reproduction",
      "Cherry-picking data points or excluding 'outliers' without justification"
    ]
  }
};